Streetbeat News

GUTS

Fractyl Health Inc.

Industry

Surgical and Medical Instrument Manufacturing

Open

1.29

Mkt cap

62M

Volume

265K

High

1.30

P/E Ratio

-0.78

52-wk high

8.37

Low

1.23

Div yield

N/A

52-wk low

1.16

Fractyl Health reported a net loss of $17.2 million for Q2. This financial result may impact investor sentiment and the stock price of the company.

Portfolio Pulse from Benzinga Newsdesk

August 14, 2024 | 8:24 pm

Fractyl Health, Inc. (NASDAQ:GUTS) announced new clinical results from its German Real-World Registry, showing significant weight loss and blood sugar reduction in patients with obesity and Type 2 Diabetes after a single Revita endoscopic procedure. The results indicate a median weight loss of nearly 13% and a substantial decrease in HbA1c levels over 12 months.

Portfolio Pulse from Benzinga Newsdesk

August 08, 2024 | 12:08 pm

Fractyl Health shares are trading higher after the company received FDA Device Designation for Revita, aimed at weight maintenance for people with obesity who discontinue GLP-1 based drugs.

Portfolio Pulse from Benzinga Newsdesk

July 30, 2024 | 11:25 am

Fractyl Health has received FDA device designation for its Revita treatment, aimed at weight maintenance for people with obesity who discontinue GLP-1 based drugs.

Portfolio Pulse from Benzinga Newsdesk

July 30, 2024 | 11:05 am

Fractyl Health, Inc. (NASDAQ:GUTS) is accelerating its REMAIN-1 clinical study and expanding the protocol for its REVITALIZE-1 study, potentially increasing the U.S. treatment population for its Revita device by nearly six-fold. The company aims to provide durable weight maintenance and enhanced glucose regulation for patients with obesity and type 2 diabetes (T2D). Key data from these studies are expected between Q4 2024 and mid-2025.

Portfolio Pulse from Benzinga Newsdesk

June 24, 2024 | 10:07 am

Fractyl Health, Inc. (NASDAQ:GUTS) presented new preclinical data on its Rejuva pancreatic gene therapy program for obesity and type 2 diabetes at the American Diabetes Association's 84th Scientific Sessions. The study showed promising results in maintaining body composition and glycemia in a mouse model after semaglutide withdrawal.

Portfolio Pulse from Benzinga Newsdesk

June 24, 2024 | 7:12 am

Fractyl Health, Inc. (NASDAQ:GUTS) presented new preclinical data showing that a single administration of its Rejuva pancreatic gene therapy reduced fat mass and improved glycemia in a diet-induced obesity mouse model. The data was presented at the American Diabetes Association's 84th Scientific Sessions and highlighted as one of the President's Select Abstracts.

Portfolio Pulse from Benzinga Newsdesk

June 23, 2024 | 6:35 pm

The article highlights the performance of 12 health care stocks during Thursday's after-market session. Notable gainers include Venus Concept (VERO), Cyclacel Pharmaceuticals (CYCC), and Applied DNA Sciences (APDN). Significant losers include Biomea Fusion (BMEA), Tevogen Bio Holdings (TVGN), and Bright Green (BGXX).

Portfolio Pulse from Benzinga Insights

June 06, 2024 | 8:31 pm

Fractyl Health, Inc. (NASDAQ:GUTS) presented preclinical data from its Rejuva pancreatic gene therapy program at Digestive Disease Week 2024, focusing on a single-administration GLP-1 therapy for obesity and type 2 diabetes.

Portfolio Pulse from Benzinga Newsdesk

May 20, 2024 | 10:04 am

Fractyl Health (NASDAQ:GUTS) reported a significant improvement in its Q1 2024 financial results with a GAAP EPS of $(0.17), up from $(7.87) YoY, and sales of $33,000, a 560% increase from $5,000 YoY.

Portfolio Pulse from Benzinga Newsdesk

May 13, 2024 | 10:12 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.